Sharma PS, Sharma R, Tyagi T: Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. Curr Pharm Des 2009, 15:758-776.Sharma PS, Sharma R, Tyagi T. Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. Curr Pharm Des. 2009;15: 758-76....
Receptor Tyrosine Kinase Inhibitors are molecules that block the activity of specific receptors involved in neuroinflammatory processes, which can contribute to the progression of Alzheimer's disease by preventing the overactivation of these receptors. ...
Receptor tyrosine kinase inhibitors as anti-angiogenic agents. Curr Opin Investig Drugs 2004;5:596-604.Kim DW, Lu B, Hallahan DE. Receptor tyrosine kinase inhibitors as anti-angiogenic agents. Curr Opin Investig Drugs 2004;5:597-604Kim DW, Lu B and Hallahan DE (2004) Receptor tyrosine ...
1. Objective To explore the protective role of the receptor tyrosine kinase inhibitor in chondrocyte in vitro. 目的通过对体外培养软骨细胞的实验研究,探寻受体酪氨酸激酶抑制剂对软骨细胞在细胞分子水平的影响及其可能机制。更多例句>> 2) RTK inhibitors 酪氨酸激酶受体抑制剂...
Bartolotti M, Franceschi E, Brandes AA (2012) EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer. Expert Rev Anticancer Ther 12:1429–1435. : 10.1586/era.12.121
网络释义 1. 受体酪氨酸激酶抑制剂 酪氨酸激酶... ... ) Receptor tyrosine kinase inhibitor 受体酪氨酸激酶抑制剂 ) Tyrosine kinase inhibitors 酪氨酸激酶抑制剂 ... www.dictall.com|基于8个网页 例句 释义: 全部,受体酪氨酸激酶抑制剂 更多例句筛选 1. Gefitinib, an epidermal growth factor receptor ...
; Sunitinib (Sutent) ; Vascular endothelial growth factor receptor (VEGFR) inhibitors Definition Receptor tyrosine kinase inhibitors (RTKIs) are a class of low molecular weight, membrane-permeable, ATP-competitive compounds that inhibit the enzymatic activity and function of receptor tyrosine kinases. Re...
The first results of clinical trials based on the use of RTK inhibitors in thyroid cancer patients have recently been published. Here we discuss targeting of specific RTKs as a potential therapeutic strategy for the treatment of thyroid cancer....
kinase and, subsequently, its downstream signaling, conferring oncogenic properties [32,36,37]. Numerous large international clinical trials have now shown that patients whose tumors harbor activating somaticEGFRTKD mutations are uniquely sensitive to treatment with EGFR tyrosine kinase inhibitors (TKIs) ...
Receptor tyrosine kinase inhibitors improve cancer survival but their cardiotoxicity requires investigation. We investigated these inhibitors’ effects on human cardiac progenitor cells in vitro and rat heart in vivo. We applied imatinib, sunitinib or so